SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke
📍 Aftermath
The SINGLE‑AF trial reported that oral anticoagulants, including contemporary DOACs, lowered the risk of stroke in patients with atrial fibrillation at intermediate risk. Separate findings indicated that edoxaban did not reduce stroke and was associated with increased bleeding, especially after intracranial hemorrhage.
Epilogue added 32d ago, after coverage quieted.
Where it stands
- Velocity & Diffusion: Coverage escalated across 10 distinct news outlets with 12 published articles, achieving a live velocity of 9.
- Predictive Outlook: Newsylist algorithmic models forecast this story will remain a dominant headline through tomorrow.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermediate Risk For Stroke" developed substantial multi-source reporting across the Health sector, tracked across 10 distinct newsrooms by Newsylist.
Key reporting was led by en.sedaily.com, Korea Biomedical Review, medscape.com and News-Medical. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.
Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 32d ago.
Sources (12)
Answered
What drove coverage for SINGLE-AF: DOAC Therapy vs. No Anticoagulation in AFib Patients at Intermed?
Coverage spiked when 10 independent newsrooms published 12 verified reports during this coverage cycle.
How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.